Combination versus sequential single agent chemotherapy for metastatic breast cancer
about
Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic IndexA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerSequence of treatment in locally advanced and metastatic renal cell carcinomaAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.SEOM clinical guidelines in metastatic breast cancer 2015.Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician surveySalvianolic acid B protects against myocardial damage caused by nanocarrier TiO2; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO2 nanoparticlesDefining the optimal sequence for the systemic treatment of metastatic breast cancer.Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy.Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Metastatic breast cancer: The Odyssey of personalization.Advancing Immunotherapy in Metastatic Breast Cancer.Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.Practical consensus recommendations on management of triple-negative metastatic breast cancer.Preparation and characterization of an injectable thermosensitive hydrogel for simultaneous delivery of paclitaxel and doxorubicin.
P2860
Q26751245-62E63935-A600-4F70-9DC2-71DF8E171AF6Q26752846-818095BC-E6AA-444E-A39A-B099C6E67E49Q26773653-C2E428A5-CB37-4F8D-9DD8-B88FD1671738Q27343148-4333AAE3-7A93-4DF6-8918-B331E61E2DF3Q28080469-5D97C2F8-B5EC-463E-9D87-6C5D29663CF6Q30317067-DC5361B1-C75B-4B53-80AD-E3D5D4C12E1BQ34567456-33918234-AB1E-428A-919F-4A4C8736FADEQ36171900-25C83459-E896-4CB8-93D2-0CB0205F07DBQ36400360-B571DEFA-AFD8-4601-B0B3-6B930A6CA338Q36528355-38A31F1D-A972-47D2-AD63-68BDBF397F3AQ37398335-731A8B1D-02CC-4B59-AC36-9276FDD506F9Q37588645-1AC01F0D-2A78-435D-B59F-3F1E0335B094Q37716468-5A22D53B-82E6-4AAD-AB1B-4A9F57AB55FBQ38741802-B0C2DEA8-9E66-47D0-B3F7-47ADC7A5D051Q38836010-A5921D55-AE44-46BC-A0B9-008D96EB347DQ38901163-5C3C75CF-56D0-464C-AB85-B9CF3BEB5EB9Q39324161-948A2C6D-8F35-48CE-BDB7-403100FBF059Q39848776-D27A8DCF-6E34-4529-BCD9-96945D0F6E77Q40233516-896C39EF-F0D8-4FA0-AEC3-B5B32C65AA27Q47132531-DA03D7C1-8F8E-4A42-9032-04751C621E06Q48213752-9EDD50B2-C9A6-4561-A6EB-20FB5F018B21Q48274719-6A661016-B87F-4795-A8A7-5E6B5169DB89Q55120303-22766CEB-3101-46BA-8B6A-C5FB4DE9F67BQ55269862-B0B25E8E-586D-4340-87E6-FC5F13D38C40
P2860
Combination versus sequential single agent chemotherapy for metastatic breast cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@ast
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en-gb
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@nl
type
label
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@ast
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en-gb
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@nl
prefLabel
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@ast
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en-gb
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@nl
P2093
P2860
P3181
P1476
Combination versus sequential single agent chemotherapy for metastatic breast cancer
@en
P2093
Alexandra Barratt
Marisa C Jenkins
Martin HN Tattersall
Rachel F Dear
P2860
P3181
P356
10.1002/14651858.CD008792.PUB2
P577
2013-12-18T00:00:00Z